Panbela Therapeutics, Inc. · OTC:PBLA

Panbela Therapeutics — Investor Presentation (January 2022)

22 slides from Panbela Therapeutics's investor presentation, January 2022

  1. Slide 1: Company Overview

    Company Overview January, 2022 Last modified on 1/3/22

  2. Slide 2: Cautionary Statements

    Cautionary Statements Certain statements in this presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act. Forward-looking statem

  3. Slide 3: Company Highlights

    Company Highlights New Therapeutic Class For Solid Tumors ― Developing small molecule polyamine metabolic inhibitors with tumor and organ-specific preferential uptake ― Multiple cancer types with known elevated polyamine levels represent potential targets ― Novel Trojan Horse polyamine metabolic inh

  4. Slide 4: Panbela Leadership Team and Board of Directors

    Panbela Leadership Team and Board of Directors  Collectively developed 10 FDA-approved therapies generating billions in sales Leadership Team Board of Directors Jennifer K. Simpson, PhD, MSN, CRNP Michael T. Cullen, MD, MBA, ABIM President & CEO Jennifer K. Simpson, PhD, MSN, CRNP Susan Horvath, CP

  5. Slide 5: Pancreatic Cancer: a Major Unmet Medical Need

    Pancreatic Cancer: a Major Unmet Medical Need  Globally, the number of deaths caused by, and incidence of, pancreatic cancer has more than doubled from 1990 to 2017 5-Year Survival Rate (U.S.) Deaths in the U.S. (Thousands) 100% 98% 160 90% Lowest survival rate 3rd leading cause 136 among major can

  6. Slide 6: Objective Response Rate Comparison Among Prior PDAC Trials

    Objective Response Rate Comparison Among Prior PDAC Trials  In addition to strong ORR results, 70% of SBP-101 patients presented CA 19-9 biomarker reductions of greater than 60% MPACT Registration Trial Halozyme Cohort 4 + P1b Interim P3 P3 Ongoing Approved and SOC Discontinued 60% 70% 70% 48% +25p

  7. Slide 7: Increased Polyamine Levels Can Enhance the Malignant Potential of Cancer Cells

    Increased Polyamine Levels Can Enhance the Malignant Potential of Cancer Cells and May Decrease Anti-Tumor Immunity  Many tumors maintain greatly elevated levels of polyamines to support their rapid growth and survival ‒ Of all human tissues, the pancreas has the highest level of native spermidine

  8. Slide 8: SBP-101 MOA (Trojan Horse): Synthetic Polyamine Analogue

    SBP-101 MOA (Trojan Horse): Synthetic Polyamine Analogue  SBP-101 is a synthetic analogue of spermine being designed to exploit the self-regulating nature of polyamine metabolism  SBP-101 preferentially accumulates in tumor cells and downregulates the polyamine metabolic pathway, lowering producti

  9. Slide 9: Area of Future Exploration: SBP-101 Combined with IOs

    Area of Future Exploration: SBP-101 Combined with IOs  Historical clinical trials using IO agents have been unsuccessful  A potential hypothesis is that excess polyamines, especially spermine, insulate the tumor microenvironment from immune cells  SBP-101 is a synthetic analogue of spermine, whic

  10. Slide 10: Significant SBP-101 Polyamine Metabolic Inhibitor Pipeline Expansion Opportunity

    Significant SBP-101 Polyamine Metabolic Inhibitor Pipeline Expansion Opportunity Upregulated polyamine metabolism is also a phenotypic change caused by certain oncogenic mutations, creating potential for future patient stratification strategies in other cancers Discovery Preclinical IND Ready Phase

  11. Slide 11: SBP-101: Human Tumor Inhibition in Pre-Clinical Studies

    SBP-101: Human Tumor Inhibition in Pre-Clinical Studies Near Complete Tumor Inhibition in Mice(1) Reduction of Tumor Volume in Mice(2) 1400 8,000 Untreated Control 7,199 1200 7,000 SBP-101 reduction in tumor volume vs. control SBP-101 15 mg/kg 6,000 and vs. Gemcitabine alone 1000 Mean Tumor Burden (

  12. Slide 12: SBP-101 Shows Greater Inhibition of Human PDA Growth Than Standard of Care

    SBP-101 Shows Greater Inhibition of Human PDA Growth Than Current Standard of Care (Gem + Nab) in an in vitro Study SBP-101 Demonstrates Superior and Additive Efficacy in vitro Gemcitabine + Nab-Paclitaxel SBP-101 Gemcitabine + Nab-Paclitaxel + SBP-101 100 90 80 70 60 % Inhibition 50 40 30 20 10 0 A

  13. Slide 13: SBP-101 Phase 1 PDA Study Design

    SBP-101 Phase 1 PDA Study Design* Overview Design  Open-label P1A/1B study to assess safety, tolerability and PK Dose Enrolled Dosing Schedule when combined with Nab-Paclitaxel and Gemcitabine Cohort 1 (n = 4) 0.2 mg/kg only  Identify P2 dose and schedule and assess preliminary efficacy of 3-drug

  14. Slide 14: Clinical Importance of CA 19-9 Biomarker

    Clinical Importance of CA 19-9 Biomarker  Carbohydrate antigen (CA) 19-9 is a type of antigen found in the blood that is often elevated in pancreatic disease  Studies have suggested that decreases in CA 19-9 levels are correlated with improved prognosis; ≥60-75% declines in CA 19-9 levels correlat

  15. Slide 15: CA 19-9 Biomarker and Survival Benefit Correlation

    CA 19-9 Biomarker and Survival Benefit Correlation  Patients in the MPACT study (Phase III Gem+Nab) whose CA 19-9 levels decreased saw an approximate 5-month incremental median survival benefit (P=.001) compared to patients with unchanged or increased CA 19-9 levels  Greatest survival benefit obse

  16. Slide 16: Maximum CA 19-9 Percent Change From Baseline by Response

    Interim Cohort 4 + P1B CA 19-9 Positive Biomarker Data  70% of subjects had a maximum CA 19-9 decrease greater than 60%  90% of subjects had a decrease in CA 19-9 levels CA 19-9 tumor marker often released by 1 pancreatic cancer cells 0.8 Maximum CA 19-9 Percent Change From Baseline by 0.6 0.4 Pat

  17. Slide 17: SBP-101 Interim ORR Data

    SBP-101 Interim ORR Data  3.1x the response rate of Gemcitabine & Nab-Paclitaxel in Cohort 2 SBP-101 Well  2.1x the response rate in Cohort 4 + P1B Tolerated in  2.1x the disease control rate of Gemcitabine & Nab-Paclitaxel in Cohort 2 Combination with  1.5x the disease control rate in Cohort 4

  18. Slide 18: Interim Response Rate by Patient

    Interim Response Rate by Patient  N = 29 across Cohort 4 and P1B (0.4 mg/kg)  N = 7 across Cohort 2 (0.4 mg/kg)  ORR: 48%  71% partial response (5 of 7)  3% Complete Response (1 of 29)(1)  29% stable disease (2 of 7)  45% Partial Response (13 of 29) (2)  34% stable disease (10 of 29)  2 pat

  19. Slide 19: Interim Results

    Interim Results  Gemcitabine (G, Gemzar, Eli Lilly) & Nab-Paclitaxel (A, Abraxane, Celgene):  Standard pancreatic cancer Rx combination  Grade 3-4 neutropenia 38%  Grade 3-4 thrombocytopenia 13%  Grade 3-4 peripheral neuropathy 17%  SBP-101  No added neutropenia, thrombocytopenia, or neuropat

  20. Slide 20: Cash Balance and Capitalization

    Cash Balance and Capitalization Cash Balance as of September 30, 2021 $14,072,000 Capitalization Table Common Stock Outstanding as of September 30, 2021 13,434,152 Stock Options @ $5.87 WAEP 2,489,136 Restricted Stock Units Outstanding 16,185 Warrants @ $4.59 WAEP 5,109,501 Fully Diluted Shares Outs

  21. Slide 21: Milestones

    Milestones 2022 ► First Patient Enrolled in randomized phase 2 study (1Q’22) ► ASCO GI Poster Presentation (1Q – January) ► First Patient Enrolled – Neoadjuvant Pancreatic Trial (1Q'22) ► Final Data from phase 1 trial (1H'22) ► Initiate Ovarian Cancer Clinical Program(1H’22) Panbela Therapeutics 21

  22. Slide 22: SBP-101 Summary

    SBP-101 Summary Unique dual-attack MOA is synergistic with other agents, potentially enhancing anti-tumor response Favorable safety & tolerability profile and subcutaneous administration in clinical studies to date supports potential ease of use Interim data from Phase 1a/1b trial to be presented at

Panbela Therapeutics — Investor Presentation (January 2022) on 6ix